WATCHMAN FLX versus NOAC for Embolic Protection in the Management of Patients with Non-Valvular Atrial Fibrillation

Brief description of study

The study will research the safety and effectiveness of the WATCHMAN FLXTM device compared to treatment with NOAC therapy to determine if it works for patients with your type of atrial fibrillation who require treatment for potential blood clot formation (thrombus) in the left atrial appendage (LAA). The medications used in this study are already approved for use in your country. This study will compare WATCHMAN FLXTM to a category of OAC called non-vitamin K antagonist oral anticoagulation, also known as NOACs. NOAC medications include Pradaxa® (dabigatran), Eliquis® (apixaban), Xarelto® (rivaroxaban), or Savaysa® (edoxaban).


Clinical Study Identifier: s20-01380
ClinicalTrials.gov Identifier: NCT04394546
Principal Investigator: Larry A Chinitz.
Other Investigator: Anthony Aizer.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.